Sinovac Biotech Ltd. (NASDAQ: SVA) Stock Competitors & Peer Comparison

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, RPRX has a market cap of 25.9B. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while RPRX trades at $58.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas RPRX's P/E ratio is 11.13. In terms of profitability, SVA's ROE is -0.01%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, SVA is less volatile compared to RPRX. This indicates lower risk in terms of short-term price fluctuations for SVA.Check RPRX's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, CORT has a market cap of 11.9B. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while CORT trades at $110.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas CORT's P/E ratio is 315.11. In terms of profitability, SVA's ROE is -0.01%, compared to CORT's ROE of +0.08%. Regarding short-term risk, SVA is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for SVA.Check CORT's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas WBA's P/E ratio is -1.64. In terms of profitability, SVA's ROE is -0.01%, compared to WBA's ROE of -0.57%. Regarding short-term risk, SVA is similarly volatile compared to WBA. This indicates similar risk in terms of short-term price fluctuations for SVA.Check WBA's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, LQDA has a market cap of 5.9B. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while LQDA trades at $66.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas LQDA's P/E ratio is 477.71. In terms of profitability, SVA's ROE is -0.01%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, SVA is less volatile compared to LQDA. This indicates lower risk in terms of short-term price fluctuations for SVA.Check LQDA's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, KNSA has a market cap of 5.9B. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while KNSA trades at $77.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas KNSA's P/E ratio is 85.82. In terms of profitability, SVA's ROE is -0.01%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, SVA is less volatile compared to KNSA. This indicates lower risk in terms of short-term price fluctuations for SVA.Check KNSA's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, PBH has a market cap of 2.1B. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while PBH trades at $44.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas PBH's P/E ratio is 10.17. In terms of profitability, SVA's ROE is -0.01%, compared to PBH's ROE of +0.09%. Regarding short-term risk, SVA is less volatile compared to PBH. This indicates lower risk in terms of short-term price fluctuations for SVA.Check PBH's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas HROWL's P/E ratio is N/A. In terms of profitability, SVA's ROE is -0.01%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, SVA is less volatile compared to HROWL. This indicates lower risk in terms of short-term price fluctuations for SVA.Check HROWL's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, LTGO has a market cap of 1.4B. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while LTGO trades at $22.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas LTGO's P/E ratio is N/A. In terms of profitability, SVA's ROE is -0.01%, compared to LTGO's ROE of N/A. Regarding short-term risk, SVA is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for SVA.Check LTGO's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas HROWM's P/E ratio is N/A. In terms of profitability, SVA's ROE is -0.01%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, SVA is less volatile compared to HROWM. This indicates lower risk in terms of short-term price fluctuations for SVA.Check HROWM's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, HELP has a market cap of 766.7M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while HELP trades at $12.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas HELP's P/E ratio is -2.97. In terms of profitability, SVA's ROE is -0.01%, compared to HELP's ROE of -0.71%. Regarding short-term risk, SVA is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for SVA.Check HELP's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, CUVL has a market cap of 297.5M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while CUVL trades at $5.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas CUVL's P/E ratio is N/A. In terms of profitability, SVA's ROE is -0.01%, compared to CUVL's ROE of N/A. Regarding short-term risk, SVA is less volatile compared to CUVL. This indicates lower risk in terms of short-term price fluctuations for SVA.Check CUVL's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, CELG-RI has a market cap of 242.7M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while CELG-RI trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, SVA's ROE is -0.01%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, SVA is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for SVA.Check CELG-RI's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, HITI has a market cap of 226.7M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while HITI trades at $2.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas HITI's P/E ratio is -7.57. In terms of profitability, SVA's ROE is -0.01%, compared to HITI's ROE of -0.36%. Regarding short-term risk, SVA is less volatile compared to HITI. This indicates lower risk in terms of short-term price fluctuations for SVA.Check HITI's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, CTOR has a market cap of 106M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while CTOR trades at $1.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas CTOR's P/E ratio is -2.43. In terms of profitability, SVA's ROE is -0.01%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, SVA is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for SVA.Check CTOR's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while ATLN trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas ATLN's P/E ratio is -0.68. In terms of profitability, SVA's ROE is -0.01%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, SVA is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for SVA.Check ATLN's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, SDEV has a market cap of 52.2M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while SDEV trades at $1.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas SDEV's P/E ratio is -0.18. In terms of profitability, SVA's ROE is -0.01%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, SVA is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for SVA.Check SDEV's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas RAD's P/E ratio is -0.05. In terms of profitability, SVA's ROE is -0.01%, compared to RAD's ROE of +2.76%. Regarding short-term risk, SVA is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for SVA.Check RAD's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while GLTO trades at $21.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas GLTO's P/E ratio is -1.78. In terms of profitability, SVA's ROE is -0.01%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, SVA is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for SVA.Check GLTO's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, NSRX has a market cap of 29.7M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while NSRX trades at $3.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas NSRX's P/E ratio is -4.78. In terms of profitability, SVA's ROE is -0.01%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, SVA is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for SVA.Check NSRX's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, SCYX has a market cap of 28M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while SCYX trades at $4.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas SCYX's P/E ratio is -1.30. In terms of profitability, SVA's ROE is -0.01%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, SVA is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for SVA.Check SCYX's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, COSM has a market cap of 17.9M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while COSM trades at $0.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas COSM's P/E ratio is -0.45. In terms of profitability, SVA's ROE is -0.01%, compared to COSM's ROE of -1.19%. Regarding short-term risk, SVA is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for SVA.Check COSM's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, BFRI has a market cap of 16.9M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while BFRI trades at $1.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas BFRI's P/E ratio is -2.40. In terms of profitability, SVA's ROE is -0.01%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, SVA is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for SVA.Check BFRI's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, CNSY has a market cap of 14M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while CNSY trades at $2.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas CNSY's P/E ratio is -0.48. In terms of profitability, SVA's ROE is -0.01%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, SVA is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for SVA.Check CNSY's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, SCNX has a market cap of 12.7M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while SCNX trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas SCNX's P/E ratio is -0.15. In terms of profitability, SVA's ROE is -0.01%, compared to SCNX's ROE of -0.54%. Regarding short-term risk, SVA is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for SVA.Check SCNX's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, BFRIW has a market cap of 11.4M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while BFRIW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, SVA's ROE is -0.01%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, SVA is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for SVA.Check BFRIW's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas CJJD's P/E ratio is -0.46. In terms of profitability, SVA's ROE is -0.01%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, SVA is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for SVA.Check CJJD's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas SSY's P/E ratio is -2.86. In terms of profitability, SVA's ROE is -0.01%, compared to SSY's ROE of -0.09%. Regarding short-term risk, SVA is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for SVA.Check SSY's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, POM has a market cap of 5.4M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while POM trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas POM's P/E ratio is -0.16. In terms of profitability, SVA's ROE is -0.01%, compared to POM's ROE of +0.16%. Regarding short-term risk, SVA is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for SVA.Check POM's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, BGMS has a market cap of 5.2M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while BGMS trades at $0.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas BGMS's P/E ratio is -0.26. In terms of profitability, SVA's ROE is -0.01%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, SVA is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for SVA.Check BGMS's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, PAVS has a market cap of 3.5M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while PAVS trades at $4.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas PAVS's P/E ratio is -0.05. In terms of profitability, SVA's ROE is -0.01%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, SVA is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for SVA.Check PAVS's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, EOCN has a market cap of 3.5M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while EOCN trades at $3.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas EOCN's P/E ratio is -0.24. In terms of profitability, SVA's ROE is -0.01%, compared to EOCN's ROE of N/A. Regarding short-term risk, SVA is less volatile compared to EOCN. This indicates lower risk in terms of short-term price fluctuations for SVA.Check EOCN's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas MDVL's P/E ratio is -0.05. In terms of profitability, SVA's ROE is -0.01%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, SVA is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for SVA.Check MDVL's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas ATNFW's P/E ratio is N/A. In terms of profitability, SVA's ROE is -0.01%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, SVA is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for SVA.Check ATNFW's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, SVA's ROE is -0.01%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, SVA is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for SVA.Check BGMSP's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas AZNH's P/E ratio is 38.35. In terms of profitability, SVA's ROE is -0.01%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, SVA is less volatile compared to AZNH. This indicates lower risk in terms of short-term price fluctuations for SVA.Check AZNH's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, SVA's ROE is -0.01%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, SVA is similarly volatile compared to LFLYW. This indicates similar risk in terms of short-term price fluctuations for SVA.Check LFLYW's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, PRPH has a market cap of 175.2K. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while PRPH trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas PRPH's P/E ratio is N/A. In terms of profitability, SVA's ROE is -0.01%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, SVA is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for SVA.Check PRPH's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, OREX has a market cap of 0. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas OREX's P/E ratio is -0.14. In terms of profitability, SVA's ROE is -0.01%, compared to OREX's ROE of -0.54%. Regarding short-term risk, SVA is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for SVA.Check OREX's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, POZN has a market cap of 0. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas POZN's P/E ratio is N/A. In terms of profitability, SVA's ROE is -0.01%, compared to POZN's ROE of +0.61%. Regarding short-term risk, SVA is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for SVA.Check POZN's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas SHPG's P/E ratio is 11.35. In terms of profitability, SVA's ROE is -0.01%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, SVA is similarly volatile compared to SHPG. This indicates similar risk in terms of short-term price fluctuations for SVA.Check SHPG's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas ESRX's P/E ratio is 10.69. In terms of profitability, SVA's ROE is -0.01%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, SVA is similarly volatile compared to ESRX. This indicates similar risk in terms of short-term price fluctuations for SVA.Check ESRX's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas IPXL's P/E ratio is -10.11. In terms of profitability, SVA's ROE is -0.01%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, SVA is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for SVA.Check IPXL's competition here

Sinovac Biotech Ltd. (NASDAQ: SVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SVA stands at 464.9M. In comparison, CPD has a market cap of 0. Regarding current trading prices, SVA is priced at $6.47 on the NASDAQ, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SVA currently has a P/E ratio of -5.68, whereas CPD's P/E ratio is N/A. In terms of profitability, SVA's ROE is -0.01%, compared to CPD's ROE of N/A. Regarding short-term risk, SVA is less volatile compared to CPD. This indicates lower risk in terms of short-term price fluctuations for SVA.Check CPD's competition here